

1 2 3 4 5 6 7 8 14 18 19 20 21 22

chain bonds :

1-11 2-16 11-12 11-13 13-14 13-17 22-23

ring bonds :

1-2 1-5 2-3 3-4 3-6 4-5 4-8 6-7 7-8 14-18 14-22 18-19 19-20 20-21
21-22

exact/norm bonds :

1-2 1-5 1-11 2-3 2-16 3-4 3-6 4-5 4-8 6-7 7-8 11-12 11-13 13-14 13-17
14-18 14-22 18-19 19-20 20-21 21-22 22-23

G1:C,S

G2:H,CH3

G3:C,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 11:CLASS 12:CLASS
13:CLASS 14:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 C,S

G2 H,Me

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s 11 full

FULL SEARCH INITIATED 12:54:36 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 554 TO ITERATE

100.0% PROCESSED 554 ITERATIONS
SEARCH TIME: 00.00.01

83 ANSWERS

L2 83 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 12:54:42 ON 15 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Feb 2006 VOL 144 ISS 8

FILE LAST UPDATED: 14 Feb 2006 (20060214/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2

L3 4 L2

=> d ibib abs hitstr 1-4

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

ACCESSION NUMBER: 2005:216670 CAPLUS

DOCUMENT NUMBER: 142:298003

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

2005:216670 CAPLUS

142:298003

Preparation of thieno[3,2-b]pyrrole amide derivatives

as glycogen phosphorylase inhibitors

Birch, Alan Martin; Simpson, Iain; Stocker, Andrew;

Whittamore, Paul Robert Owen

AstraZeneca AB, Sweden; AstraZeneca UK Limited

PCT Int. Appl., 84 pp.

CODENT: PHX02

Patent

English

Same inventors



| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2005020987 | A1 | 20050310 | WO 2004-GB3648 | 20040827 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPL. INFO.: GB 2003-20422 A 20030830


OTHER SOURCE(S): MARPAT 142:298003

GI




AB Title compds. represented by the formula I [wherein B = (un)substituted pyrrolyl-2-carbonyl or indolyl-2-carbonyl; R1 = independently halo, nitro,

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847684-49-5 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,6-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847684-50-8 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,6-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

carbamoyl, alkanoyloxy, etc.; R2 = H, (hydroxy)alkyl, alkylcarbamoyl, etc.; A = pyridylene ring; n = 0 or 1; and pharmaceutically acceptable salts or prodrugs thereof) were prep. as glycogen phosphorylase inhibitors. For example, II was given in a multi-step synthesis starting from

4,5-dichlorothiophene-2-carboxaldehyde. II showed thermodyn. soly. (16.2 μM) and plasma-protein binding activity with 0.06 μM. Thus, I and their pharmaceutical compds. are useful as glycogen phosphorylase inhibitors for the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, hyperglucagonemia, cardiac ischemia or obesity in a warm-blooded animal, such as man (no data).

IT 847684-47-3P 847684-48-4P 847684-49-5P

847684-50-8P 847684-51-9P 847684-52-0P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)

RN 847684-47-3 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847684-48-4 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847684-51-9 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,8-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847684-52-0 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,8-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 847684-45-1P 847684-46-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)


RN 847684-45-1 CAPLUS

CN 1,5-Naphthyridine-1(2H)-acetic acid, 3-[(1,2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847684-46-2 CAPLUS
CN 1,5-Naphthyridine-1(2H)-acetic acid, 3-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonylamino]-3,4-dihydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 600157-44-6P 600157-52-6P 600157-53-7P
847684-40-6P 847684-41-7P 847684-42-8P
847684-43-9P 847684-44-0P 847684-53-1P
847684-54-2P 847684-55-3P 847684-56-4P
847684-57-5P 847684-58-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)
RN 600157-44-6 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847684-41-7 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-1-(3-hydroxypropyl)-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 847684-42-8 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-1,6-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 847684-43-9 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-52-6 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 600157-53-7 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 847684-40-6 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-1-(3-hydroxypropyl)-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 847684-44-0 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 847684-53-1 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-1-(2-(methylsulfonyl)ethyl)-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 847684-54-2 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-1-(2-(methylsulfonyl)ethyl)-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 847684-55-3 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 847684-56-4 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847684-57-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 847684-74-6P 847684-75-7P 847684-76-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)
 RN 847684-74-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847684-75-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847684-58-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)



IT 847684-72-4P 847684-73-5P
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)
 RN 847684-72-4 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847684-73-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847684-76-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-1-[2-(methylthio)ethyl]-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD

FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:589248 CAPLUS
 DOCUMENT NUMBER: 141:140474
 TITLE: Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
 INVENTOR(S): Sher, Philip M.; Ellsworth, Bruce A.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 43 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|------------|
| US 2004142938 | A1 | 20040722 | US 2003-712823 | 20031113 |
| PRIORITY APPLN. INFO.: | | | US 2002-426465P | P 20021114 |

OTHER SOURCE(S): MARPAT 141:140474
 GI




AB Prodrugs of glycogen phosphorylase inhibiting compds. are provided, said prodrug compds., G(-O2CR')m(-OH)n(-O2C(CH2)pCH3)q [G = branched or straight C3-5-carbon chain and (-O2CR'), (-OH) and (-O2C(CH2)pCH3) are attached to any available carbon atom along G; m = 1 - 4; n = 0 - 3; p = 0 - 16; q = 0 - 3; where m + n + q = 3 or 4; and -O2CR' is a fragment of a compound I wherein W = W1, W2, W3; X = O, S, SO2, CHR5, , CHR5O, CHR5S, CHR5SO2, CHR5CO, CH2CHR5; Y = bond, CHR6; Z = aryl, heteroaryl; R1 = H, alkyl, alkenyl; R2 = H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkenyl; R3, R4 = H, halo, CF3, CN, alkyl, alkoxy; R5, R6 = H, alkyl, aryl, alkenyl, CN, CN4R9A (tetrazole), CO2R9A, CONR9AR9B, CONR9AOR9B; A = CH,

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PAGE 1-B



L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 B = O, S; wherein R1, R2, R5, R6, R7, R8 = alkyl, aryl, alkenyl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy and each may be substituted with 1 - 3 hydrogen bonding groups. Thus, 3-[(5-chloroindolecarbonyl)amino]-3,4-dihydrocarboxytril I (R1 = R2 = H, W = 5-chloroindole, X = CH2, YZ = benzo) was prepd. from 3-amino-3,4-dihydrocarboxytril via acylation with 5-chloroindolecarboxylic acid resin-bound 2,3,5,6-tetrafluorophenyl ester. Further provided are pharmaceutical compns. and methods for treating diabetes and related diseases employing compds. above, either alone or in combination with another therapeutic agent.
 IT 724783-28-2P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compds.)
 RN 724783-28-2 CAPLUS
 CN 4-Quinoloneacetic acid, 3-[[[(2-bromo-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-1,2,3,4-tetrahydro-2-oxo-, 1,2,3-propanetriyl ester, (3R,3'R,3''R,4S,4'S,4''S)-(9CI) (CA INDEX NAME)





L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:719489 CAPLUS
 DOCUMENT NUMBER: 139:261278
 TITLE: Preparation of heterocyclic amides as inhibitors of glycogen phosphorylase
 INVENTOR(S): Birch, Alan Martin; Morley, Andrew David; Stocker, Andrew; Whittamore, Paul Robert Owen
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 126 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2003074532 | A1 | 20030912 | WO 2003-GB877 | 20030304 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GN, HE, LS, MW, NL, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2477667 | AA | 20030912 | CA 2003-2477667 | 20030304 |
| AU 2003214377 | A1 | 20030916 | AU 2003-214377 | 20030304 |
| BR 2003008146 | A | 20041207 | BR 2003-8146 | 20030304 |
| EP 1483270 | A1 | 20041208 | EP 2003-1483270 | 20030304 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, SK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| US 2005131015 | A1 | 20050616 | US 2003-506741 | 20030304 |
| JP 2005526058 | T2 | 20050902 | JP 2003-573000 | 20030304 |
| NO 2004003852 | A | 20040914 | NO 2004-3852 | 20040914 |
| PRIORITY APPLN. INFO.: | | | GB 2002-5165 | A 20020306 |
| | | | WO 2003-GB877 | W 20030304 |

OTHER SOURCE(S): MARPAT 139:261278
 GI

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB The title compds. [I; X = N, CH; R4 and R5 together are either SCR6:CR7 or CR7:CR6S; R6, R7 = H, halo, alkyl, etc.; A = phenylene or heteroarylene; n = 0-2; R1 = halo, NO2, CN, OH, CO2H, etc.; R2 = H, OH, CO2H; R3 = H, OH, aryl, heterocyclyl, etc.] which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity such as diabetes


type II, were prepared. Thus, amidation of 5-carboxy-2-chloro-6H-thieno[2,3-b]pyrrole with Me (3-amino-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate (preps. given) in the presence of HOBt and EDCI in DMF afforded 76% II. The compds. I showed IC50 values in the range 100µM to 1nM against hrl glycogen phosphorylase a (hr1 GPa). Pharmaceutical composition comprising the compound I was claimed.

IT 600157-07-1P 600157-08-2P 600157-16-2P
600157-18-4P 600157-23-1P 600157-26-4P
600157-27-5P 600157-28-6P 600157-32-2P
600157-38-8P 600157-41-3P 600157-42-4P
600157-47-9P 600157-49-1P 600653-76-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thienopyrrolecarboxamides as inhibitors of glycogen phosphorylase)
RN 600157-07-1 CAPLUS
CN 1(2H)-Quinolineacetic acid, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-08-2 CAPLUS
CN 1(2H)-Quinolineacetic acid, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 600157-16-2 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 600157-18-4 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-23-1 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-[2-oxo-2-[(3aR,6aS)-tetrahydro-2,2-dimethyl-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethyl]-3-quinolinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 600157-26-4 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-27-5 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-[3-hydroxy-2-(hydroxymethyl)propyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-28-6 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 600157-32-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1-(cyanomethyl)-1,2,3,4-
 tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



RN 600157-38-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1,2,3,4-tetrahydro-1-[2-
 (methylthio)ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-41-3 CAPLUS
 CN 1(2H)-Quinolineacetic acid, 3-[[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX
 NAME)



RN 600157-42-4 CAPLUS
 CN 1(2H)-Quinolineacetic acid, 3-[[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 600157-09-3P 600157-10-6P 600157-11-7P
 600157-12-9P 600157-13-9P 600157-14-0P
 600157-15-1P 600157-17-3P 600157-19-5P
 600157-20-8P 600157-21-9P 600157-22-0P
 600157-24-2P 600157-25-3P 600157-29-7P
 600157-30-0P 600157-31-1P 600157-33-3P
 600157-34-4P 600157-35-5P 600157-36-6P
 600157-37-7P 600157-39-9P 600157-40-2P
 600157-43-5P 600157-44-6P 600157-45-7P
 600157-46-8P 600157-48-0P 600157-50-4P
 600157-52-6P 600157-53-7P 600157-54-8P
 600157-55-9P 600157-73-1P 600157-74-2P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of thienopyrrolecarboxamides as inhibitors of glycogen
 phosphorylase)

RN 600157-09-3 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-10-6 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-47-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1,2,3,4-tetrahydro-1-(3-
 hydroxypropyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-49-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-
 oxo-1-(2-oxobutyl)-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600653-76-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[1-[(2Z)-2-amino-2-
 (hydroxyimino)ethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-2-chloro-
 (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-11-7 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-12-8 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-N-hydroxy-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-13-9 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-N-(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX
 NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-14-0 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1,2,3,4-tetrahydro-1-(2-
 hydroxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-15-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1-(2,3-dihydroxypropyl)-
 1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-17-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(3R)-1-[(2S)-2,3-
 dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-21-9 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonylamino]-3,4-dihydro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-oxo-
 (9CI) (CA INDEX NAME)




RN 600157-22-0 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonylamino]-3,4-dihydro-N-(2-methoxyethyl)-2-oxo- (9CI) (CA INDEX
 NAME)




RN 600157-24-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[2-[(3R,4S)-3,4-

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-19-5 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(3R)-1-[(2R)-2,3-
 dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.




RN 600157-20-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1,2,3,4-tetrahydro-1-[2-
 (4-hydroxy-1-piperidinyl)-2-oxoethyl]-2-oxo-3-quinolinyl]- (9CI) (CA
 INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dihydroxy-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-2-oxo-3-
 quinolinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 600157-25-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[2-
 (dimethylamino)ethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA
 INDEX NAME)




RN 600157-29-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide,
 2,3-dichloro-N-[1,2,3,4-tetrahydro-
 1-[3-hydroxy-2-(hydroxymethyl)propyl]-2-oxo-3-quinolinyl]- (9CI) (CA
 INDEX NAME)




RN 600157-30-0 CAPLUS


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1(2H)-Quinolineacetamide, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-yl]carbonyl]amino]-N-(2,3-dihydroxypropyl)-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-31-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-(2-methoxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-33-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-37-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[1-[(5-amino-1,3,4-oxadiazol-2-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 600157-39-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-(2-methylsulfinylethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-40-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-(2-methylsulfonyl)ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 600157-34-4 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-[(1H-tetrazol-5-yl)methyl]-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-35-5 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-yl]carbonyl]amino]-3,4-dihydro-N-(methylsulfonyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-36-6 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-43-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-44-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 600157-45-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[3-(dimethylamino)-2-hydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-46-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-2-oxo-1-[(2-oxo-1,3-dioxan-5-yl)methyl]-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 600157-48-0 CAPLUS
 CN 1(2H)-Quinolinepropanamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-3,4-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-50-4 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-1-(2-hydroxybutyl)-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-73-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(3S)-1-[(2S)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 600157-74-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 600157-56-0P 600157-59-3P 600157-61-7P
 600157-63-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thienopyrrolecarboxamides as inhibitors of glycogen phosphorylase)
 RN 600157-56-0 CAPLUS


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-52-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 600157-53-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 600157-54-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(6-fluoro-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 600157-55-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-6-methoxy-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 600157-59-3 CAPLUS
 CN 1(2H)-Quinolineacetic acid, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-3,4-dihydro-2-oxo-, hydrazide (9CI) (CA INDEX NAME)




RN 600157-61-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-63-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,1-dimethylethyl)dimethylsilyloxy]propyl-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2002:185126 CAPLUS
 DOCUMENT NUMBER: 136:247485
 TITLE: Preparation of bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
 INVENTOR(S): Bartlett, Julie B.; Freeman, Sue; Kenny, Peter; Morley, Andrew; Whittamore, Paul
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2002020530 | A1 | 20020314 | WO 2001-SE1880 | 20010831 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2417594 | A1 | 20020314 | CA 2001-2417594 | 20010831 |
| AU 2001082833 | A5 | 20020322 | AU 2001-82833 | 20010831 |
| EP 1317459 | A1 | 20030611 | EP 2001-961577 | 20010831 |
| EP 1317459 | B1 | 20040407 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2001013606 | A | 20030624 | BR 2001-13606 | 20010831 |
| JP 20040508376 | T2 | 20040318 | JP 2002-525151 | 20010831 |
| AT 263772 | E | 20040415 | AT 2001-961577 | 20010831 |
| NZ 524011 | A | 20040827 | NZ 2001-524011 | 20010831 |
| PT 1317459 | T | 20040831 | PT 2001-961577 | 20010831 |
| ES 2217183 | T3 | 20041101 | ES 2001-1261577 | 20010831 |
| EE 200300083 | A | 20041215 | EE 2003-83 | 20010831 |
| ZA 2003001013 | A | 20040505 | ZA 2003-1013 | 20030205 |
| US 2003232875 | A1 | 20031218 | US 2003-344506 | 20030210 |
| NO 200301024 | A | 20030305 | NO 2003-1024 | 20030305 |
| BG 107624 | A | 20040130 | BG 2003-107624 | 20030310 |
| HK 1055299 | A1 | 20041021 | HK 2003-107519 | 20031016 |
| PRIORITY APPLN. INFO.: | | | GB 2000-21831 | A 20000906 |
| | | | WO 2001-SE1880 | W 20010831 |

OTHER SOURCE(S): MARPAT 136:247485
 GI

10/344506
 pending

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. I [R1 = H, halo, NO2, CN, OH, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, NO2, CH2F, CHF2, CF3, amino, alkyl, alkenyl, alkoxy, etc.; R3 = H, alkyl; -X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5-, -CR4=CR5-O-, -N-CR4-S-, -S-CR4=N-, -NR3-CR4=CR5- and -CR4=CR5-NR3- wherein R4 and R5 = independently H, halo, CN, alkyl, ureido, NO2, etc.; n = 0-4] or a pharmaceutically acceptable salt or an

in vivo hydrolyzable ester thereof were prepared possessing glycogen phosphorylase inhibitory activity (no data). Thus, II was prepared by amidation of 5-carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole with 2-phenoxylethylamine. As glycogen phosphorylase inhibitors, I have value in the treatment of disease states associated with increased glycogen phosphorylase activity, e.g., type 2 diabetes. Pharmaceutical compns. containing I are described.

IT 403859-70-1P 403859-94-9P 403859-96-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound: preparation of thienopyrrolyl amides as glycogen phosphorylase inhibitors)


RN 403859-70-1 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 403859-94-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-(1,2,3,4-tetrahydro-2-

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

exo-3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 403859-96-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

These 3 compounds
 are proviso-out.